MD Anderson Physicians Network Symposium Changing Paradigms in Cancer Treatment and Patient Management
JW Marriott San Francisco Union Square
500 Post Street, San Francisco California.
San Francisco, California
This symposium will consist of four days focused on providing information on the changing paradigms in diagnostic and therapeutic interventions as they pertain to cancer treatment and management of selected tumor types. Many of the didactic presentations and interactive case presentations with the audience are designed to highlight new information and answer controversial oncologic questions. The practitioner attending the symposium will receive the updated information from MD Anderson Cancer Center faculty and national clinical leaders. This program is intended to improve practitioner knowledge and performance, patient management and outcomes.

The information provided during this symposium will be beneficial to medical oncologists, hematologists, radiation oncologists, surgical oncologists, general surgeons, thoracic surgeons, internists, physician
assistants, advanced practice nurses and oncology nurses involved in the care of patients with breast, colorectal, esophageal, head and neck, hematologic, non-small cell lung, pancreatic and prostate cancers.

After attending the symposium, participants should be able to

    * Identify and apply the changing paradigms in cancer treatment that pertain to patients with breast, colorectal, esophageal, head and neck, NSCLC, hematologic, pancreatic and prostate cancers (Knowledge, Competence, Performance);
    * Describe and apply novel diagnostic and cancer therapeutic approaches now being used and accepted that impact patient management and outcomes (Knowledge, Competence, Performance, Patient Outcomes);
    * Adopt the role and timing of each discipline (medical, radiation, and surgery) in patient management (Knowledge, Competence, Performance);
    * Implement new knowledge in patient management for better outcomes (Knowledge, Competence, Performance, Patient Outcomes).

Schedule of Presentations:

Saturday, July 30, 2011
06:30:00 Continental Breakfast | Registration
07:00:00 Introduction and Welcome William A. Murphy
07:10:00 Keynote Speaker | Cancer Care Delivery in a Time of Healthcare Reform Thomas W. Feeley
07:55:00 Thoracic/Esophageal/Head & Neck Cancers
08:00:00 Lung Cancer Screening Works! Now What? Reginald Munden
08:20:00 What is the Surgeon’s Participation in Contemporary Management of Lung Cancer? Stephen G. Swisher
08:45:00 Break
08:55:00 Small Cell Lung Cancer | Current Strategies and New Directions Bonnie S. Glisson
09:20:00 Non-Small Cell Lung Cancer | Combined Modality Therapy for Patients with Stage II/III Disease Scott M Lippman
09:45:00 Stereotactic and Proton Radiation for Non-Small Cell Lung Cancer Melinda Jeter
10:10:00 Advances in Novel Therapeutics for Lung Cancer Edward S. Kim
10:40:00 Break
10:50:00 Current Approaches in the Management of Squamous Cell and Adenocarcinoma of the Esophagus Stephen G. Swisher
11:20:00 Combined Modality Management for Head and Neck Cancer Patients with HPV-Positive Disease: Strategies to Maintain Efficacy and Reduce Long Term Toxicity Merrill S. Kies
11:45:00 New Evidence for IMRT and Proton Therapy and the Emerging Role for Both in the Management of Head and Neck Cancers Steven J. Frank
12:10:00 Break
12:25:00 Appropriate Imaging for Diagnostic and Follow-Up of Head and Neck Cancer Lawrence E. Ginsberg
12:50:00 Challenging Thoracic, Esophagus, and Head and Neck Case Presentations and Interactive Audience Participation Merrill S. Kies
14:00:00 Adjourn
18:30:00 Welcome Reception
Sunday, July 31, 2011
06:45:00 Continental Breakfast | Registration
06:55:00 Breast Cancer
07:00:00 Introduction Kelly K. Hunt
07:05:00 Breast Cancer Screening and the Impact of Breast Density Wei Yang
07:25:00 Genetic Testing and the Impact on Decision Making Banu K. Arun
07:45:00 Processing of Sentinel Nodes and the Significance of Micrometastases Aysegul A. Sahin
08:05:00 Excisional Biopsy for Breast Cancer Diagnosis is Not Justified Anthony Lucci
08:25:00 Break
08:40:00 Should We Still Be Performing Axillary Lymph Node Dissection In Breast Cancer? Kelly K. Hunt
09:00:00 Partial Breast Irradiation
09:20:00 What is the Appropriate Margin in Breast Conserving Surgery? Karen Hoffman
09:40:00 HER-2 Testing in Breast Cancer: What Are the Issues? Aysegul A. Sahin
10:00:00 Break
10:15:00 Making Sense of Multigene Assays in Practice Ana Gonzalez-Angulo
10:35:00 When Should We Use MRI in Breast Cancer Follow-Up? Wei Yang
10:55:00 HER-2 Directed Therapies: Adjuvant or Neoadjuvant? Ana Gonzalez-Angulo
11:15:00 What is the Role for Surgical Resection in Patients with Stage IV Disease? Kelly K. Hunt
11:35:00 Break
11:50:00 The Case for Postmastectomy Radiation Therapy Karen Hoffman
12:10:00 Do Circulating Tumor Cells and Disseminated Tumor Cells Add Value in Prognosis and Treatment? Anthony Lucci
12:30:00 Challenging Breast Cancer Case Presentations and Interactive Audience Participation Kelly K. Hunt
14:00:00 Adjourn
Monday, August 1, 2011
06:45:00 Continental Breakfast | Registration
07:00:00 Introduction Merrill S. Kies
07:05:00 Keynote Lecture | ASCO Highlights 2011: Practice Changing Research Everett E Vokes
07:40:00 Hematologic Cancers
07:45:00 Lymphoma and Myeloma Introduction Peter W. McLaughlin
07:50:00 PET Scan in Lymphoma: Which Histologies? When? Can it Guide Treatment? Fredrick B Hagemeister
08:15:00 Therapy Selection in DLBCL Based on Molecular Subtype Sven de Vos
08:40:00 Break
08:50:00 New Therapeutic Targets in Lymphoma | The B-cell Receptor, CD-30 Fredrick B Hagemeister
09:15:00 Front Line Combination and Maintenance Strategies In Myeloma Sheeba K. Thomas
09:40:00 Leukemia Introduction Miloslav Beran
09:45:00 Emerging Paradigms in the Management of Myeloproliferative Disorders Stefan Faderl
10:10:00 Molecular Markers Guiding Diagnosis and Optimizing Management of Leukemias Stefan Faderl
10:35:00 Break
10:45:00 Challenging Lymphoma, Myeloma, and Leukemia Case Presentations and Interactive Audience Participation Miloslav Beran, Peter W. McLaughlin
11:45:00 Break
12:00:00 Miscellaneous
12:05:00 Active Surveillance vs. Treatment in the Management of Prostate Cancer Deborah Kuban
12:25:00 New Options for Therapy in Localized Pancreatic Cancer Jason B. Fleming
12:50:00 Dose Escalation and Stereotactic Therapy in the Management of Pancreatic Cancer Sunil Krishnan
13:15:00 Challenging Case Presentations and Interactive Audience Participation Jason B. Fleming, Deborah Kuban
14:00:00 Adjourn
Tuesday, August 2, 2011
06:45:00 Continental Breakfast | Registration
06:55:00 Colorectal Cancers
07:00:00 Introduction George J. Chang
07:05:00 Image Enhanced Endoscopic Detection and Advanced Endoscopic Intervention of Colorectal Neoplasia Roy Soetikno
07:30:00 Imaging Evaluation of Colorectal Cancer: X-rays, Magnets or Metabolic Agents? Harmeet Kaur
07:55:00 Adjuvant Chemotherapy for Colorectal Cancer: Where To Now? Cathy Eng
08:20:00 Immunohistochemistry, PCR, and Genomics for Colorectal Pathology: When, Why, and For Whom? Melissa Taggart
08:45:00 Break
09:00:00 Diffusion Weighted MRI in Staging and ResponseMonitoring for Rectal Cancer Harmeet Kaur
09:25:00 Advances in RT: IMRT, Short Course and Selective Omission of RT Sunil Krishnan
09:50:00 Advances in Minimally Invasive Surgery for Rectal Cancer: Local Excision or Robotics? George J. Chang
10:15:00 Making Sense of the Alphabet Soup in Advanced Colorectal Cancer: Novel Agents in Preclinical Development Cathy Eng
10:40:00 Break
10:55:00 Surgical Therapy for Metastatic Colorectal Cancer: When to Refer and To Whom?
11:20:00 Quality Assurance and Recurrence Risk Reduction in the Surgical Treatment of Colorectal Cancer George J. Chang
11:45:00 What the Blood Compartment Can Teach Us About Colorectal Cancer: Circulating Tumor Cells and DNA Melissa Taggart
12:10:00 Break
12:25:00 Challenging Colorectal Cancer Case Presentations and Interactive Audience Participation George J. Chang
14:00:00 Adjourn
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.